Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: ytica  limited  pericoach  women  pelvic  bladder  health  kegel  muscle  exercise  training  medical  device  multivu  7543451  jadenu  novartis  iron  chelator  chelation  therapy  blood  transfusions  treatment  medicine  medication  multivu  7440151  after  the  fall  patricia  gussin  after  the  fall  by  patricia  gussin  book  trailer  medical  thriller  fiction  suspense  fda  sus  enteromedics  vbloc  vagal  blocking  maestro  system  obesity  weight  loss  hunger  medical  device  treatment  multivu  7269351  janssen  imbruvica  leukaemia  lymphoma  blood  cancer  treatment  multivu  72762540  rescueonefinancial  rescue1financial  cologuard  exact  sciences  colon  cancer  fda  approval  dna  screening  test  home  testing  health  multivu  7092251  novoeight  haemophilia  treatment  blood  clot  coagulate  approval  study  healthcare  multivu  71400529  cochlear  nucleus  hybrid  system  implant  ski  slope  high  frequency  hearing  loss  aids  multivu  7150651  adenocarcinoma  appendix  cancer  patients  health  immunotherapy  dendritic  cell  vaccine  multivu  64654  eurazeo  moncler  borsa  italiana  milan  stock  exchange  French  luxury  fashion  business  finance  multivu  64154  lung  cancer  alliance  uspstf  ct  scans  screening  medicare  insurance  coverage  health  multivu  62719 
Search // approval
Results 13-24 of 33 for ' approval ' (0 seconds)
The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads. The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress. To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
Categories // People and Blog 
Added: 3201 days ago by MultiVuVideos
Runtime: 1m11s | Views: 686 | Comments: 1
Not yet rated
 

 

 

Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Added: 3285 days ago by MultiVuVideos
Runtime: 0m53s | Views: 765 | Comments: 2
Not yet rated
 

 

 

An injury ends Laura Nelson’s career as a surgeon. Now, as Vice President of a pharmaceutical company, Laura works to finalize the approval of a groundbreaking new drug. But her efforts are being thwarted by a malicious FDA employee who will stop at nothing to prevent the approval, and Laura is standing directly in his path. Find out more about the author here- http://patriciagussin.com/ and check out the book here http://oceanviewpub.com/after-the-fall/. After the Fall by Patricia Gussin. Thriller
Categories // Miscellaneous 
Added: 3330 days ago by cosproductions
Runtime: 1m-0s | Views: 692 | Comments: 0
     
 

 

 

EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Added: 3361 days ago by MultiVuVideos
Runtime: 0m24s | Views: 648 | Comments: 2
Not yet rated
 

 

 

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Categories // People and Blog  Business 
Added: 3450 days ago by MultiVuVideos
Runtime: 1m39s | Views: 847 | Comments: 2
Not yet rated
 

 

 

Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Categories // People and Blog  Business 
Added: 3516 days ago by MultiVuVideos
Runtime: 2m14s | Views: 749 | Comments: 2
Not yet rated
 

 

 

Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Categories // Science and Technology 
Added: 3608 days ago by MultiVuVideos
Runtime: 1m51s | Views: 703 | Comments: 2
Not yet rated
 

 

 

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced the U.S. Food and Drug Administration (FDA) approval and launch of the Cochlear™ Nucleus® Hybrid Implant System, a revolutionary new hybrid hearing solution that helps people who may hear a little but are still missing a lot, even with their hearing aids. The Nucleus Hybrid System is a unique combination of proven solutions, which allows people to get back what they've been missing by amplifying the low-pitched hearing a person does have while restoring access to the high-pitched hearing they've lost. People who are candidates for the technology no longer have to worry about straining to hear with their hearing aids as the Nucleus Hybrid System will allow them to maximize their hearing in all frequencies. To view the Multimedia News Release, go to http://www.multivu.com/mnr/7150651-cochlear-fda-approval-u-s-launch-cochlear-nucleus-hybrid-implant-system
Categories // Business  Science and Technology 
Added: 3656 days ago by MultiVuVideos
Runtime: 2m20s | Views: 855 | Comments: 2
Not yet rated
 

 

 

In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes. The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own. To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Categories // People and Blog 
Added: 3766 days ago by MultiVuVideos
Runtime: 4m46s | Views: 795 | Comments: 1
Not yet rated
 

 

 

Moncler S.p.A. announces that today it has obtained approval from CONSOB for the Prospectus for the Initial Public Offering issued for the purpose of the admission of the Company’s ordinary shares to trading on the Mercato Telematico Azionario organized and managed by Borsa Italiana S.p.A.. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64154-Eurazeo-Moncler-IPO-clearance
Categories // Fashion and Lifestyle  Business 
Added: 3769 days ago by MultiVuVideos
Runtime: 0m37s | Views: 831 | Comments: 0
Not yet rated
 

 

 

The USPSTF today issued a draft recommendation giving its second highest approval rating for CT screening for lung cancer for those at high risk, a move that if approved in final form, will trigger Medicare and insurance coverage and bring about a dramatic drop in the leading cause of cancer deaths. Today, LCA also launched its Risk Navigator tool – www.AtRiskForLungCancer.org. Additionally, it expanded the hours of its support line – (800) 298-2436 – operating 8 a.m. to 7 p.m. EST. LCA will also launch a national educational advertising campaign in September to encourage the public to know their risk for lung cancer. To view the Multimedia News Release, go to http://www.multivu.com/mnr/62719-lung-cancer-alliance-uspstf-recommends-ct-screening-for-lung-cancer
Categories // News and Politics 
Added: 3895 days ago by MultiVuVideos
Runtime: 0m48s | Views: 1941 | Comments: 0
Not yet rated
 

 

 

In a revolutionary treatment for early-onset scoliosis (EOS), a team of surgeons implanted adjustable growing rods in two children from California. The pioneering surgeries — the first ever in the United States — were performed on May 7th at Rady Children’s Hospital in San Diego. The Food and Drug Administration (FDA) granted Compassionate Use approval to use the MAGEC™ (MAGnetic Expansion Control) System, developed by Ellipse Technologies, Inc., for these two patients. To view Multimedia News Release, go to http://www.multivu.com/mnr/61604-rady-children-s-hospital-san-diego-ellipse-magec-early-onset-scoliosis-eos
Categories // Science and Technology 
Added: 3977 days ago by MultiVuVideos
Runtime: 1m51s | Views: 2612 | Comments: 0
Not yet rated
 

 

 

Page 2 of 3  |  Go to page     |  ««FIRST «Previous  Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.